Imiquimod vs cidofovir: Total serious adverse events
Summary of findings for imiquimod showed no clear difference in total serious adverse events compared with cidofovir (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings for imiquimod vs cidofovir Total serious adverse events · women with usual‐type vulval intraepithelial neoplasia Summary of findings for imiquimod showed no clear difference in total serious adverse events compared with cidofovir (moderate certainty). Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia (2016) · Cochrane Headline outcomes only | RR 1.26 [0.88, 1.81] | 1 study · 168 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia 2016 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.